文献速递骨肌MR

基于MRI的骨肿瘤报告与数据系统(OT-RADS):前瞻性实施的临床经验与诊断准确性

MRI-BASED osseous tumour reporting and data system (OT-RADS): clinical experience of prospective implementation and diagnostic accuracy.
PubMed 文献 · Clin Radiol · 2025-11-17

研究将基于MRI的骨肿瘤报告与数据系统(OT-RADS)前瞻性整合入电子口述系统后,回顾性分析2021年7月至2024年5月连续352例四肢或体壁骨病变患者的MRI报告。OT-RADS诊断准确性高于传统描述性印象(95.4% vs. 88.0%,p<.0001),在活检确诊、良性及恶性病变亚组中均更优。作者认为结果支持更广泛采用OT-RADS作为标准化框架。

要点

  • OT-RADS总体诊断准确性95.4%,高于描述性印象的88.0%(p<.0001)。
  • 活检确诊病例中OT-RADS准确性84.6%,高于描述性报告的61.5%(p<.0001)。
  • 良性(II-III级)与恶性(IV-V级)病变中OT-RADS准确性均持续更优(p=.003;p<.001)。

核心结论

  • OT-RADS在良恶性骨肿瘤中的诊断准确性显著优于描述性报告,结果支持更广泛采用OT-RADS作为标准化框架以分层病变风险、优化管理并改善患者结局。

研究设计与样本

  • 前瞻性将OT-RADS整合入电子口述系统后,由经过专科培训的骨肌放射科医生在日常骨肿瘤报告中应用OT-RADS评分;随后回顾性纳入2021年7月至2024年5月连续352例年龄17-100岁、经MRI评估且由手术、活检或良性随访确认的四肢或体壁骨病变患者;采用McNemar检验比较诊断准确性。

诊断标准与关键数值

  • OT-RADS诊断准确性95.4% vs. 描述性印象88.0%(p<.0001);活检确诊病例中OT-RADS准确性84.6% vs. 描述性报告61.5%(p<.0001);良性病变(II-III级)准确性更优(p=.003);恶性病变(IV-V级)准确性更优(p<.001);亚组分析显示OT-RADS IV级(p=.0078)和V级(p=.0156)差异显著;病变分布为OT-RADS I级4.8%、II级46.1%、III级18.2%、恶性疑似IV-V级36.1%。

临床应用与阅片要点

  • 作者认为结果支持更广泛采用OT-RADS作为标准化框架,以分层病变风险、优化管理并改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate clinical performance and diagnostic accuracy of the MRI-based Osseous Tumour Reporting and Data System (OT-RADS) compared with traditional descriptive impressions.

MATERIALS AND METHODS: After prospective integration of OT-RADS into the electronic dictation system, fellowship-trained musculoskeletal radiologists applied OT-RADS scoring in routine bone tumour reporting. This retrospective review included consecutive patients from July 2021 to May 2024, aged 17-100 years, with extremity or body wall osseous lesions evaluated by MRI and confirmed by surgery, biopsy, or benign follow-up. Demographics, imaging findings, lesion characteristics, biopsy results, treatments, and outcomes were collected. Diagnostic accuracy was compared using McNemar's test.

RESULTS: The study included 352 patients (60.2 % female, mean age 54.7 ± 15.7 years). Most lesions (66.1 %) were managed conservatively, while surgery and chemotherapy each accounted for 8.4 %. Biopsy was performed in 18.8 %. The distribution included OT-RADS I (4.8 %), II (46.1 %), III (18.2 %), and malignant-suspicion categories IV-V (36.1 %). Outcomes were favorable in 60.8 % of patients. OT-RADS demonstrated higher diagnostic accuracy than descriptive impressions (95.4 % vs. 88.0 %; p<.0001), particularly in biopsy-confirmed cases (84.6 % vs. 61.5 %; p<.0001). Accuracy was consistently superior across benign (II-III; p=.003) and malignant lesions (IV-V; p<.001), with subgroup analysis confirming significance for OT-RADS IV (p=.0078) and V (p=.0156).

CONCLUSIONS: OT-RADS significantly outperforms descriptive reporting in accuracy for benign and malignant bone tumours. These results support broader adoption of OT-RADS as a standardized framework to stratify lesion risk, optimize management, and improve patient outcomes.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Croley GC, Taneja AK, Silva FD, et al. MRI-BASED osseous tumour reporting and data system (OT-RADS): clinical experience of prospective implementation and diagnostic accuracy. Clin Radiol. 2025. PMID: 41380648. doi:10.1016/j.crad.2025.107179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。